|
Cancer type
|
Cell line
|
FL118 EC50 (95%CI) (nM)
|
SN-38 EC50 (95% CI) (nM)
|
RP
|
RR(FL118)
|
RR(SN-38)
|
|---|
|
NSCLC
|
H460
|
0.31 (0.21-0.47)
|
2.84 (1.98-4.09)
|
9.2
| | |
| |
EKVX
|
0.56 (0.38-0.83)
|
2.58 (1.73-3.80)
|
4.6
| | |
| |
A549
|
0.86 (0.61-1.22)
|
4.17 (2.30-7.57)
|
4.8
| | |
|
Colorectal cancer
|
SW620
|
0.30 (0.19-0.46)
|
1.82 (1.06-3.10)
|
6.1
| | |
| |
HCT8
|
0.28 (0.15-0.53)
|
2.21 (1.38-3.55)
|
7.9
| | |
| |
HCT116
|
0.36 (0.27-0.48)
|
3.15 (2.42-4.10)
|
8.8
| | |
| |
HCT116-SN6
|
2.28 (1.70-3.05)
|
7.63 (6.14-9.48)
|
3.3
|
6.3
|
2.4
|
| |
HCT116-G7
|
4.14 (2.78-6.16)
|
20.3 (13.9-29.6)
|
4.9
|
11.5
|
6.4
|
| |
HCT116-SN50
|
4.04 (2.79-5.86)
|
135 (80.4-226)
|
33.4
|
11.2
|
42.9
|
| |
HCT116-A2
|
2.13 (1.48-3.07)
|
51.5(37.4-70.8)
|
24.2
|
5.9
|
16.3
|
- 95% CI = 95% confidence interval.
- RP = Relative potency, calculated by dividing the EC50 of SN-38 by the EC50 of FL118.
- RR = Relative resistance, calculated by dividing the EC50 of indicated drug in resistant cell line by EC50 in parental cell line.
